Naama Maimon

Title: Naama Maimon: Innovator in Immune Response Prediction

Introduction

Naama Maimon is a notable inventor based in Nir Etzion, Israel. She has made significant contributions to the field of immunology, particularly in understanding how immune cell proportions can predict responses to treatments for inflammatory bowel disease (IBD). Her innovative work has implications for improving patient outcomes in the treatment of IBD.

Latest Patents

Naama Maimon holds a patent titled "Infiltrating immune cell proportions predict anti-TNF response in colon biopsies." This patent provides methods for predicting the responsiveness of a subject with IBD to a tumor necrosis factor (TNF)-alpha inhibitor. The methods involve analyzing the frequency of specific subpopulations of immune cells in tissue biopsies. Additionally, the patent includes methods for selecting appropriate treatments and kits designed to determine a subject's responsiveness to TNF-alpha inhibitors.

Career Highlights

Throughout her career, Naama Maimon has worked with esteemed institutions, including the Technion Research & Development Foundation Limited and Leland Stanford Junior University. Her research has focused on the intersection of immunology and therapeutic response, contributing valuable insights to the medical community.

Collaborations

Naama has collaborated with notable colleagues, including Shai S Shen-Orr and Elina Starovetsky. These collaborations have furthered her research and expanded the impact of her work in the field of immunology.

Conclusion

Naama Maimon's innovative contributions to predicting treatment responses in IBD highlight her role as a leading inventor in the field of immunology. Her work not only advances scientific understanding but also has the potential to improve treatment strategies for patients suffering from inflammatory bowel disease.